In this episode of the Better Science Better Health podcast, Gwen and Petra take on another jargon-heavy stretch of the Vital Health Podcast with Steve Potts and Duane Schulthess and unpack what is really being said about biotech financing, drug development, and the policy rules shaping investment.
In this episode, Gwen and Petra take on a Vital Health Podcast best-of about generic drug shortages and supply chain risk. They unpack the healthcare terms at the center of the discussion - generics, biologics, biosimilars, APIs, and PBMs - and explain how pricing pressure, manufacturing concentration, and reimbursement dynamics can affect whether medicines actually reach patients. 
In this first episode of the Better Science Better Health podcast, Gwen and Petra press pause on a clip from the Vital Health Podcast and unpack what is really being said, without the policy fog or economist smoke machine.
In this first episode of the Better Science Better Health podcast, Gwen and Petra press pause on a clip from the Vital Health Podcast and unpack what is really being said, without the policy fog or economist smoke machine.
Inflation Reduction Act (IRA) medicine pricing rules are reshaping therapy development and financing, with ripple effects for patient access. 
A drug approved by the US Food and Drug Administration (FDA) may not be approved by the European Medicines Agency (EMA) due to differences in regulatory frameworks, evidence expectations, and risk tolerance — not because one decision is “right” or “wrong”.